|
www.aurobindo.com |
|
|
Hyderabad, 3rd July, 2005 |
|
|
|
AUROBINDO RECEIVES - FIRST
GENERIC APPROVAL OF EFAVIRENZ |
|
|
|
Aurobindo Pharma Limited is pleased to announce
that the Company has received approval from the
USFDA for Efavirenz tablets, 600 mg. This is the
first generic approval given by US FDA to
Aurobindo ahead of the rest of pharmaceutical
industry. |
|
Efavirenz is a key ARV in the Anti AIDs therapy.
This is the third ARV approval; the other
products being, Nevirapine and Lamivudine.
Efavirenz represents a significant opportunity
in Africas for Aurobindo under PEPFAR programme.
|
|
Efavirenz is internationally called as
Sustiva,
manufactured by Bristol Myers Squibb Co.
Efavirenz is in the class of drugs called
non-nucleoside reverse transcriptase inhibitors
(NNRTIs), which helps keep the AIDS virus from
reproducing in cells. Efavirenz is very commonly
used in combination therapy. |
|
The drug will now be available for consideration
for purchase under the President’s Emergency
Plan for AIDS Relief (PEPFAR), a five-year
program being run to fight HIV/AIDS pandemic.
The Emergency Plan for AIDS Relief, which
President Bush announced, currently provides
USD15 billion to fight the HIV/AIDS over five
years, with a special focus on 15 of the
hardest-hit countries. The PEPFAR plan is
designed to prevent seven million new HIV
infections, treat at least two million
HIV-infected people, and care for ten million
HIV-affected individuals, AIDS orphans and
vulnerable children. |
|
|
|
About Aurobindo Pharma Limited |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and Active
Pharmaceutical Ingredients. The Company has
received approvals for several facilities from
leading regulatory agencies like US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa. The
company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing (Antibiotics, Anti-Retrovirals,
CVS, CNS, Gastroenterologicals, and Anti-Allergics)
around 65 APIs in the non-antibiotics and 55
APIs in the antibiotic segment. The Company is
marketing these products globally, in over 100
countries. |
|
|
|
|
|
PRESS
ROOM
